Abbonarsi

Needle-based confocal endomicroscopy for pancreatic cysts: the current agreement in interpretation - 31/05/16

Doi : 10.1016/j.gie.2015.08.080 
Kunal Karia, MD 1, Irving Waxman, MD 2, Vani J. Konda, MD 2, Frank G. Gress, MD 3, Amrita Sethi, MD 3, Uzma D. Siddiqui, MD 2, Reem Z. Sharaiha, MD 1, Prashant Kedia, MD 1, Armeen Jamal-Kabani, FNP-BC 1, Monica Gaidhane, MD 1, Michel Kahaleh, MD 1,
1 Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York, USA 
2 University of Chicago Medicine, Chicago, Illinois, USA 
3 Division of Gastroenterology, Columbia University Medical Center, New York, New York, USA 

Reprint requests: Michel Kahaleh, MD, FASGE, Chief of Endoscopy, Professor of Medicine, Medical Director, Pancreas Program, Division of Gastroenterology & Hepatology, Weill Cornell Medical College, 1305 York Avenue, 4th Floor, New York, NY 10021.Chief of Endoscopy, Professor of Medicine, Medical Director, Pancreas Program, Division of Gastroenterology & Hepatology, Weill Cornell Medical College1305 York Avenue, 4th FloorNew YorkNY 10021

Abstract

Background and Aims

Diagnosis of pancreatic cystic lesions (PCLs) remains challenging. EUS with FNA is limited by sampling error and nondiagnostic cytology. Needle-based confocal laser endomicroscopy (nCLE) performed during EUS can be used to improve diagnostic yield via FNA by providing in vivo histology of PCLs. However, the interobserver agreement (IOA) of nCLE of PCLs has yet to be studied.

Methods

Fifteen deidentified nCLE video clips of PCLs were sent to 6 interventional endoscopists at 5 institutions. Six variables were assessed for IOA: presence or absence of (1) vessels, (2) villi, (3) dark clumps, (4) reticular pattern, (5) acinar cells pattern, and (6) debris. PCL interpretation was categorized as mucinous, serous, pseudocyst, malignant, or indeterminate and final diagnosis as benign, malignant, or indeterminate.

Results

IOA ranged from “poor” to “fair.” The K statistics were –.04 (SE = .05) for vessels, .16 (SE = .07) for villi, .22 (SE = .06) for dark clumps, .13 (SE = .06) for reticular pattern, .14 (SE = .06) for acinar cells pattern, .06 (SE = .06) for debris, .15 (SE = .03) for interpretation, .13 (SE = .05) for final diagnosis, and .19 (SE = .05) for image quality. The final diagnosis was malignant (10), benign (13), and indeterminate (2). The mean accuracy of the observers was 46%, with the lowest being 20% and highest being 67%.

Conclusions

The IOA and accuracy for PCL diagnosis were low. The results of this study support the need to identify and validate imaging criteria to determine whether nCLE has diagnostic value for pancreatic pathology. (Clinical trial registration number: NCT02166086.)

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : IOA, nCLE, PCL


Mappa


 DISCLOSURE: The following authors disclosed financial relationships relevant to this publication: M. Kahaleh: Consultant for Boston Scientific and Xlumena; preceptorship for MaunaKea Tech and Concordia; research grant recipient for Boston Scientific, Fuji, Pentax, MI Tech, EMcision, ASPIRE Bariatrics, GI Dynamics, W.L. Gore Associates, Cook Endoscopy, Apollo Endosurgery, MaunaKea Tech, NinePoint Medical, and Merit Medical; A. Sethi: Consultant for Boston Scientific. All other authors disclosed no financial relationships relevant to this publication.
 If you would like to chat with an author of this article, you may contact Dr Kahaleh at mkahaleh@gmail.com.


© 2016  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 83 - N° 5

P. 924-927 - maggio 2016 Ritorno al numero
Articolo precedente Articolo precedente
  • Endosonography-guided ablation of pancreatic cystic tumors: Is it justified?
  • Enrique Vazquez-Sequeiros, Fauze Maluf-Filho
| Articolo seguente Articolo seguente
  • A randomized, controlled trial to compare the efficacy and safety profile of a dexmedetomidine-ketamine combination with a propofol-fentanyl combination for ERCP
  • Rakhee Goyal, Shahbaz Hasnain, Saloni Mittal, Sharad Shreevastava

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.